John Chester

5.3k total citations
83 papers, 2.8k citations indexed

About

John Chester is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, John Chester has authored 83 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 30 papers in Oncology and 30 papers in Genetics. Recurrent topics in John Chester's work include Virus-based gene therapy research (29 papers), CAR-T cell therapy research (18 papers) and Bladder and Urothelial Cancer Treatments (18 papers). John Chester is often cited by papers focused on Virus-based gene therapy research (29 papers), CAR-T cell therapy research (18 papers) and Bladder and Urothelial Cancer Treatments (18 papers). John Chester collaborates with scholars based in United Kingdom, United States and Germany. John Chester's co-authors include Sarah E. Jackson, Richard G. Vile, Kevin J. Harrington, Alan Melcher, Rosa María Díaz, Jill Thompson, Peter J. Selby, Timothy Kottke, Margaret A. Knowles and Jian Qiao and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

John Chester

81 papers receiving 2.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
John Chester 1.2k 1.2k 995 599 320 83 2.8k
Mack N. Barnes 1.3k 1.1× 1.5k 1.3× 1.4k 1.5× 346 0.6× 262 0.8× 80 3.3k
Don Morris 1.1k 0.9× 1.4k 1.2× 907 0.9× 137 0.2× 305 1.0× 91 3.3k
Craig P. Webb 623 0.5× 2.4k 2.1× 688 0.7× 285 0.5× 301 0.9× 46 3.7k
S Jothy 844 0.7× 1.0k 0.9× 482 0.5× 366 0.6× 304 0.9× 47 3.0k
Astrid Gruber 927 0.8× 1.8k 1.5× 251 0.3× 283 0.5× 343 1.1× 99 3.5k
Susan Wong 767 0.7× 1.4k 1.2× 831 0.8× 588 1.0× 532 1.7× 50 4.0k
Philip Furmanski 577 0.5× 1.1k 0.9× 519 0.5× 240 0.4× 487 1.5× 106 3.0k
Scott A. Foster 1.5k 1.3× 2.4k 2.1× 603 0.6× 386 0.6× 361 1.1× 63 4.9k
Nobuhiko Emi 943 0.8× 1.8k 1.5× 530 0.5× 128 0.2× 609 1.9× 170 4.3k
Albert Deisseroth 2.4k 2.0× 2.6k 2.3× 937 0.9× 242 0.4× 1.0k 3.1× 139 5.7k

Countries citing papers authored by John Chester

Since Specialization
Citations

This map shows the geographic impact of John Chester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Chester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Chester more than expected).

Fields of papers citing papers by John Chester

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Chester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Chester. The network helps show where John Chester may publish in the future.

Co-authorship network of co-authors of John Chester

This figure shows the co-authorship network connecting the top 25 collaborators of John Chester. A scholar is included among the top collaborators of John Chester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Chester. John Chester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Birtle, Alison, Robert J. Jones, John Chester, et al.. (2024). Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. Journal of Clinical Oncology. 42(13). 1466–1471. 25 indexed citations
2.
Bates, Emily A., James A. Davies, Valérie S. Méniel, et al.. (2022). Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10. Molecular Therapy — Oncolytics. 25. 43–56. 6 indexed citations
3.
Patel, Meera, Eudald Felip, Rachel Sharkey, et al.. (2021). 1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19. Annals of Oncology. 32. S1142–S1142. 1 indexed citations
4.
Dettorre, Gino M, Nikolaos Diamantis, Angela Loizidou, et al.. (2020). 319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection. Annals of Oncology. 31. S1366–S1366. 3 indexed citations
5.
Uusi-Kerttula, Hanni, James A. Davies, Jill Thompson, et al.. (2018). Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. Clinical Cancer Research. 24(17). 4215–4224. 38 indexed citations
6.
7.
Uusi-Kerttula, Hanni, Mateusz Legut, James A. Davies, et al.. (2015). Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies. Human Gene Therapy. 26(5). 320–329. 35 indexed citations
8.
9.
Collins, Jemima, Simon Noble, John Chester, Bernadette Coles, & Anthony Byrne. (2014). The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open. 4(1). e003697–e003697. 94 indexed citations
10.
11.
Nicholson, Steve, Emma Hall, S.J. Harland, et al.. (2013). Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). British Journal of Cancer. 109(10). 2554–2559. 84 indexed citations
12.
Karapanagiotou, Eleni, Victoria Roulstone, Katie Twigger, et al.. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research. 18(7). 2080–2089. 151 indexed citations
13.
14.
Grimison, Peter, Mark D. Chatfield, Danish Mazhar, et al.. (2012). Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.. Journal of Clinical Oncology. 30(15_suppl). 4531–4531. 1 indexed citations
15.
Kottke, Timothy, Fiona Errington‐Mais, José S. Pulido, et al.. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine. 17(7). 854–859. 73 indexed citations
16.
Kottke, Timothy, John Chester, Elizabeth J. Ilett, et al.. (2011). Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy. Molecular Therapy. 19(10). 1802–1812. 22 indexed citations
17.
Kottke, Timothy, Geoff Hall, José S. Pulido, et al.. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. Journal of Clinical Investigation. 120(5). 1551–1560. 68 indexed citations
18.
Hall, Geoffrey, Robert J. Weeks, Jonathon Olsburgh, et al.. (2005). Transcriptional control of the human urothelial-specific gene, uroplakin Ia. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1729(2). 126–134. 8 indexed citations
19.
Chester, John, Geoffrey Hall, Martin Förster, & Andrew Protheroe. (2004). Systemic chemotherapy for patients with bladder cancer – current controversies and future directions. Cancer Treatment Reviews. 30(4). 343–358. 35 indexed citations
20.
Chester, John, B Thiele, Sylvia Janetzki, et al.. (1989). The promoter structure and complete sequence of the gene encoding the rabbit erythroid cell-specific 15-lipoxygenase. Gene. 84(2). 493–499. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mack N. Barnes Breakdown of academic impact, for papers by Don Morris Breakdown of academic impact, for papers by Craig P. Webb Breakdown of academic impact, for papers by S Jothy Breakdown of academic impact, for papers by Astrid Gruber Breakdown of academic impact, for papers by Susan Wong Breakdown of academic impact, for papers by Philip Furmanski Breakdown of academic impact, for papers by Scott A. Foster Breakdown of academic impact, for papers by Nobuhiko Emi Breakdown of academic impact, for papers by Albert Deisseroth
Rankless by CCL
2026